Carisma Therapeutics Long Term Debt

Carisma Therapeutics (CARM) currently reports a long-term debt of $610K as of September 2025. That compares with $860K in the prior-year period — down 28.9% year over year. Use the charts on this page to explore Carisma Therapeutics's long-term debt history and peer comparisons.

Carisma Therapeutics's long-term debt decreased from $860K to $610K — a 28.9% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Carisma Therapeutics reported $610K in long-term debt as of September 2025. That compares with $860K in the prior-year period — down 28.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $610K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Carisma Therapeutics, and consider following CARM for alerts when major investors trade the stock.

Carisma Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $610K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CARM with unrelated industries.